In this interview, Emile d’Angremont, MSc, discusses the results of a recent study examining the use of cholinesterase inhibitors for the management of psychotic symptoms among patients with...
In this interview, Emile d’Angremont, MSc, discusses the results of a recent study examining the use of cholinesterase inhibitors for the management of psychotic symptoms among patients with...
Gulsen Ozen, MD, answers questions about her team’s research in the use of statins to help reduce the risk of cardiovascular disease and type 2 diabetes in individuals with rheumatoid arthritis.
Gulsen Ozen, MD, answers questions about her team’s research in the use of statins to help reduce the risk of cardiovascular disease and type 2 diabetes in individuals with rheumatoid arthritis.
Gulsen Ozen, MD, answers questions about her team’s research in the use of statins to help reduce the risk of cardiovascular disease and type 2 diabetes in individuals with rheumatoid arthritis.
Gulsen Ozen, MD, answers questions about her team’s research in the use of statins to help reduce the risk of cardiovascular disease and type 2 diabetes in individuals with rheumatoid arthritis.
Gulsen Ozen, MD, answers questions about her team’s research in the use of statins to help reduce the risk of cardiovascular disease and type 2 diabetes in individuals with rheumatoid arthritis.
Gulsen Ozen, MD, answers questions about her team’s research in the use of statins to help reduce the risk of cardiovascular disease and type 2 diabetes in individuals with rheumatoid arthritis.
Gulsen Ozen, MD, answers questions about her team’s research in the use of statins to help reduce the risk of cardiovascular disease and type 2 diabetes in individuals with rheumatoid arthritis.
Gulsen Ozen, MD, answers questions about her team’s research in the use of statins to help reduce the risk of cardiovascular disease and type 2 diabetes in individuals with rheumatoid arthritis.
